Assignee
TG THERAPEUTICS INC
US·7 granted patents·7 pending applications·17 citations·filing 2013–2024
Top patents by PatentIndex Score
14 records- 0192US11965032B1Anti-CD20 antibody compositionsTG THERAPEUTICS INC·Filed 2023·Granted Apr 23, 2024·2 cites·18 claims
- 0291US11884740B1Anti-CD20 antibody compositionsTG THERAPEUTICS INC·Filed 2022·Granted Jan 30, 2024·2 cites·15 claims
- 0391US11807689B1Anti-CD20 antibody compositionsTG THERAPEUTICS INC·Filed 2022·Granted Nov 7, 2023·2 cites·22 claims
- 0489US11814439B1Anti-CD20 antibody compositionsTG THERAPEUTICS INC·Filed 2022·Granted Nov 14, 2023·2 cites·19 claims
- 0583US10966977B2Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disordersTG THERAPEUTICS INC·Filed 2017·Granted Apr 6, 2021·4 cites·20 claims
- 0678US9694071B2Combination of anti-CD20 antibody and PI3 kinase selective inhibitorTG THERAPEUTICS INC·Filed 2013·Granted Jul 4, 2017·5 cites·25 claims
- 0777US2024209110A1Anti-cd20 antibody compositionsTG THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0877US2024270863A1Anti-cd20 antibody compositionsTG THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0966US2026062495A1Commercial-scale recombinant protein production in rat hybridoma cellsTG THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1059US2020323981A1Combination of Anti-CD20 Antibody and PI3 Kinase Selective InhibitorTG THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1157US10729768B2Combination of anti-CD20 antibody and PI3 kinase selective inhibitorTG THERAPEUTICS INC·Filed 2017·Granted Aug 4, 2020·0 cites·35 claims
- 1255US2021169878A1Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disordersTG THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1350US2022143026A1Triple combination to treat b-cell malignanciesTG THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1440US2019247399A1Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancersTG THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →